Rating Rationale
March 03, 2017 | Mumbai
Mangalam Drugs and Organics Limited
 
Rating Action
Total Bank Loan Facilities Rated Rs.81 Crore
Long Term Rating CRISIL BB+/Stable (Upgraded from 'CRISIL BB/Stable')
Long Term Rating CRISIL BB+/Stable (Upgraded from 'CRISIL BB/Stable'; Continues on 'Notice of Withdrawal')
Long Term Rating Withdrawal
Short Term Rating CRISIL A4+ (Continues on 'Notice of Withdrawal'; Rating Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has upgraded its ratings on the long term bank facilities of Mangalam Drugs and Organics Limited (MDOL) to 'CRISIL BB+/Stable' from 'CRISIL BB/Stable' ; while ratings on the bank guarantee facilities of Rs.1.3 crore, cash credit facilities of Rs.31.5 crore and  letter of credit facilities of Rs.16.0 crore of MODOL continues to be on 'Notice of Withdrawal' for 90 days as against 'Notice of withdrawal' for 180 days placed on July  11, 2016; , following revised documentation shared by company in line with CRISIL's new guidelines. The ratings will be withdrawn at the end of the notice period and continue to remain under surveillance during this period. The rating action is in line with CRISIL's policy on withdrawal of its ratings on bank loans. 
 
Further CRIISL has withdrawn it's rating on the proposed long-term bank loan facility of Rs.1.8 crore of MDOL. The rating action is in line with CRISIL's policy on withdrawal of its ratings on bank loans. 
 
The rating upgrade reflects CRISIL's belief that the healthy growth in the company's scale of operations has translates into sustainable improvement in business risk profile. MDOL recorded healthy revenue growth of 40 per cent in fiscal 2016. Growth in revenue was driven by launch of new drugs and revival of demand from key export market in current year. CRISIL expects MDOL will achieve revenue growth of 15-20per cent over the medium term
 
MDOL's healthy topline growth and improvement in operating margin to 12.7 per cent in 2015-16 from 9.6 per cent in 2014-15 during the same period has resulted in improvement in its cash accruals. Even the company's financial risk profile has improved as reflected with improvement in gearing to 0.9 times from 2.2 times in 2014-15, CRISIL expects that a sustained increase in accruals will lead to gradual improvement in the company's capital structure.
 
The ratings reflect MDOL's by the extensive experience of the promoters and long track record of the company in the pharmaceutical industry, accredited manufacturing facilities, having association with Clinton Foundation and having a reputed and well-established clientele portfolio. These rating strengthen are partially offset by its relatively moderate  scale of operations in the Active Pharmaceutical Ingredients (APIs)/ Bulk Drugs Industry along with limited product offerings, client concentration risk and working capital-intensive nature of operations.

Key Rating Drivers & Detailed Description
Strengths
* Established market position and promoters' extensive experience in pharma industry: The Dhoot family, promoters of MDOL, entered the organic and inorganic pharmacological chemicals business in the early 1990s. MDOL focuses on the anti-malarial and analgesic active pharmaceutical ingredients (APIs) segments; around 85 per cent of the company's business involves the sale of APIs. The company is one of the largest players in the anti-malarial APIs segment in India. This provides MDOL a competitive advantage, in terms of experience in the research and development of anti-malarial APIs, over smaller players in the industry.  The company's credibility and the promoters' extensive industry experience have enabled it to tie up with the Clinton Foundation, for supplying APIs used in the manufacture of anti-malarial formulations
 
Weakness
* Moderate scale of operations and product concentration in revenue profile: MDOL primarily focuses on anti-malarial API segment. On account of its moderate scale of operations, the company is more exposed to competitive measures taken by large manufacturers.
 
* Working-capital-intensive operations: MDOL's operations are working capital intensive as reflected in high gross current assets (GCA) of 171 to 220 days over the past three years.
Outlook: Stable

CRISIL believes that MDOL will continue to benefit over the medium term from its established market position and its promoters' extensive industry experience. The outlook may be revised to 'Positive' if the company achieves substantial sales growth, along with a stable operating margin; leading to improvement in financial risk profile. Conversely, the outlook may be revised to 'Negative' if MDOL's sales or operating margin declines, or if it undertakes a large debt-funded capital expenditure (capex) programme, or if its working capital cycle deteriorates, leading to further weakening of its financial risk profile.

About the Company

MDOL (formerly, Advent Pharma Pvt Ltd), promoted by the Mumbai-based Dhoot family, was set up in 1972 as part of the Mangalam group. The company was reconstituted as a public limited company in 2001. MDOL manufactures bulk drugs, and organic and inorganic chemicals. MDOL is among the four World Health Organisation (WHO)-approved Indian companies to be associated with the William J Clinton Foundation (Clinton Foundation) for the manufacture of anti-malarial drugs; Clinton Foundation supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.
 
MDOL reported profit after tax (PAT) of Rs. 15.88 crore on net sales of Rs. 283.7 crore for fiscal 2016 and PAT of Rs 6.14 crore on net sales of Rs. 208.1 crore for fiscal 2015.

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Maturity Date Issue
Size
(Rs. Crore)
Rating Assigned  with Outlook
NA Bank Guarantee NA NA NA 1.3 CRISIL A4+ (Notice of Withdrawal)
NA Cash Credit NA NA NA 31.5 CRISIL BB+/Stable
(Notice of Withdrawal)
NA Letter of Credit NA NA NA 16 CRISIL A4+ (Notice of Withdrawal)
NA Proposed Long Term Bank Loan Facility NA NA NA 1.08 Withdrawal
NA Term Loan NA NA Dec-2021 14.95 CRISIL BB+/Stable
NA Working Capital Term Loan NA NA Sept-2021 16.17 CRISIL BB+/Stable
Annexure - Rating History for last 3 Years
  Current 2017 (History) 2016  2015  2014  Start of 2014
Instrument Type Quantum Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  62.62  CRISIL BB+/Stable    No Rating Change  11-07-16  CRISIL BB/Stable  27-03-15  CRISIL B+/Stable    No Rating Change  CRISIL B-/Stable 
Non Fund-based Bank Facilities  LT/ST  17.3  CRISIL A4+    No Rating Change  11-07-16  CRISIL A4+    No Rating Change    No Rating Change  CRISIL A4 
Table reflects instances where rating is changed or freshly assigned. 'No Rating Change' implies that there was no rating change under the release.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 1.3 CRISIL A4+(Notice of Withdrawal) Bank Guarantee 1.3 CRISIL A4+(Notice of Withdrawal)
Cash Credit 31.5 CRISIL BB+/Stable(Notice of Withdrawal) Cash Credit 31.5 CRISIL BB/Stable(Notice of Withdrawal)
Letter of Credit 16 CRISIL A4+(Notice of Withdrawal) Letter of Credit 16 CRISIL A4+(Notice of Withdrawal)
Proposed Long Term Bank Loan Facility 1.08 Withdrawal Proposed Long Term Bank Loan Facility 1.08 CRISIL BB/Stable(Notice of Withdrawal)
Term Loan 14.95 CRISIL BB+/Stable Term Loan 14.95 CRISIL BB/Stable
Working Capital Term Loan 16.17 CRISIL BB+/Stable Working Capital Term Loan 9.59 CRISIL BB/Stable(Notice of Withdrawal)
-- 0 -- Working Capital Term Loan 6.58 CRISIL BB/Stable
Total 81 -- Total 81 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
Criteria for rating Short-Term Debt (including Commercial Paper)

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Tanuja Abhinandan
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
tanuja.abhinandan@crisil.com

Jyoti Parmar
Media Relations
CRISIL Limited
D: +91 22 3342 1835
B: +91 22 3342 3000
 jyoti.parmar@crisil.com

Salim Yahoo
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 3031
salim.yahoo@crisil.com


Aditya Munshi
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8105
aditya.munshi@crisil.com


Rahim Keshwani
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8304
rahim.keshwani@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 95,000 MSMEs have been rated by us.



CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the “Company) you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit www.crisil.com/privacy. You can view the Company’s Customer Privacy at https://www.spglobal.com/privacy

Last updated: April 2016


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL